Navigation Links
Prasco Selected as GSK's Generics Marketing and Distribution Agent
Date:3/11/2009

Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement

MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK). FLONASE(R) (fluticasone propionate) Nasal Spray is the first product to be marketed under this agreement. Prasco, as GSK's agent and on GSK's behalf, will solicit orders for, and distribute Fluticasone Propionate Nasal Spray to all trade classes in the U.S. under a GSK/Prasco label.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090311/CL81889)

"We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry," said Prasco Chief Executive Officer E. Thomas Arington. "We look forward to working with GSK to provide more choices for patients in the generics market."

"GlaxoSmithKline is always looking for opportunities to increase access to our medicines for patients," said Stan Hull, GlaxoSmithKline Senior Vice President, U.S. Pharmaceuticals. "The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way."

Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.

FLONASE(R) is a registered trademark of Glaxo Group Limited, UK.

About Prasco

Prasco's mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with brand sameness through Prasco Authorized Generics, which are brand-products sold under the Prasco private label. Prasco's executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company's corporate capabilities is its sales/marketing and business development teams. Prasco's product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.

The company operates from a 160,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems--including DEA-approved facilities for Schedule II-V controlled drug products.

About GSK:

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com


'/>"/>
SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prasco to Distribute Generic Forms of Dorzolamide Hydrochloride-Timolol Maleate and Dorzolamide Hydrochloride Ophthalmic Solutions (Comparable to Mercks COSOPT(R) and TRUSOPT(R) Ophthalmic Solutions)
2. Brooke Franchise Corporation Announces Selected July Results
3. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
4. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
5. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
6. Fry Construction Selected for High-Profile Medical Imaging Project
7. Meth Project Advertisements Selected for National Prevention Campaign
8. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
9. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
10. SAIC Selected to Support the U.S. Military Theater Medical Information Program-Joint
11. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: